Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 6/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19840675 | 0.84 | CA12 (0.42) | CA12PRKCIKCNA3CA9 | |
| SCHEMBL22202362 | 0.83 | PPARA (0.45) | CA12KDM4EPRKCICA9 | |
| SCHEMBL24376271 | 0.76 | KDM4E (0.55) | CA12KDM4EMAPK1PRKCIKCNA3 | |
| SCHEMBL27833204 | 0.74 | LMNA (0.42) | KDM4EMAPK1KCNA3 | |
| SCHEMBL28594543 | 0.74 | GABRA1 (0.48) | KDM4EMAPK1ALOX5 | |
| SCHEMBL14205876 | 0.74 | KMT2A (0.40) | CA12KDM4EMAPK1HSD17B1ALOX5 | |
| SCHEMBL15782811 | 0.72 | CA12 (0.39) | CA12KDM4EKCNA3CA9 | |
| SCHEMBL12188715 | 0.71 | KDM4E (0.39) | KDM4EMAPK1CA9ALOX5 | |
| SCHEMBL16382260 | 0.71 | KDM4E (0.54) | KDM4EMAPK1CA9ALOX5 | |
| SCHEMBL16414537 | 0.70 | GABRA1 (0.54) | CA12PRKCIHSD17B1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160340325-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-24 | — | — | US | disclosed |
| US-9365493-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | CA12 4122/4885KDM4E 800/4885MAPK1 2095/4885 |
| US-20160340325-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | CA12 4122/4885KDM4E 800/4885MAPK1 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.